Sample Size Benefits of Replicate Design with ABE [Power / Sample Size]

posted by dshah  – India/United Kingdom, 2023-05-25 11:56 (127 d 17:20 ago) – Posting: # 23569
Views: 578

HI Sereng!

❝ (1) If you conduct a full replicate crossover design BE study (T x 2, R x 2, e.g., TRTR|RTRT) is there any sample size efficiency (fewer patients required) with ABE analysis or is it no different (in terms of sample size) than a non-replicate crossover design BE study (T x1, R x 1) with ABE analysis.

The number of observations will be same but the sample size will be half in fully replicate design compared to standard CO study.

❝ (2) For demonstrably HVD (WSV >30%), why do some product specific guidance for ANDA suggest (or allow) full replicate designs and others do not mention this approach?

For HVD, the fully replicate/partial replicate can be helpful for widening of 90% CI limit based on regulatory agency for particular PK parameters. Ethically, due to widening of 90% CI, the sample size will be less than if it has be to standard limit of 80-125%.

❝ (3) For demonstrably HVD (WSV >30%), why do some Clinical Divisions object to use of full replicate design studies in 505(b)(2) NDAs?

Not aware of any. Can you share the link?


Complete thread:

UA Flag
 Admin contact
22,763 posts in 4,775 threads, 1,627 registered users;
10 visitors (0 registered, 10 guests [including 4 identified bots]).
Forum time: 05:16 CEST (Europe/Vienna)

We should not speak so that it is possible
for the audience to understand us,
but so that it is impossible
for them to misunderstand us.    Quintilian

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz